Ceratium have helped clients win €4M of European FP7 grant funding to deliver the ODAK project. This research project to undertake the pharmaceutical development of an orphan drug for the rare infectious eye disease Acanthamoeba Keratitis which predominantly affects contact lens wearers and can result in blindness. The Ceratium team supported the project management, dissemination and exploitation activities as a consortium partner. The ODAK project started in December 2012, and has successfully completed a range of preclinical studies, a Phase I clinical study in humans and a Phase III clinical study in AK patients is now underway.

The project consortium is led by SIFI, an Italian ophthalmic company dedicated to research, development and manufacturing. The University of Rouen is the project co-ordinator, while also undertaking efficacy studies. RTC is a research organisation  based in Italy, specialising in preclinical toxicological studies. Netherlands based PSR is an award winning CRO bringing extensive expertise in clinical trials for orphan drugs to successfully design and execute the clinical trial programme. Moorfields Eye Hospital – London, UK is a key trial site in the Phase III study and brings leading AK expertise to the project. Ceratium bring a wealth of experience of EU projects to play a key role in project management, communication and dissemination activities. For more information visit: www.ODAK-project.eu